Dr. Stadler on Approved and Investigational Therapies in RCC

Walter M. Stadler, MD
Published: Tuesday, Oct 02, 2018



Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses approved and investigational therapies in renal cell carcinoma (RCC).

To date, physicians have access to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with poor- and intermediate-risk RCC. In the CheckMate-214 trial, the combination outperformed single-agent sunitinib (Sutent) in patients with metastatic RCC.

There are a number of other combinations that are being examined, adds Stadler, including PD-1 inhibitors combined with various VEGFR inhibitors. Most of the data with combinations are still pending, but in September, positive results were reported with the combination of avelumab (Bavencio) and axitinib (Inlyta). The combination was reported to show a significant improvement in progression-free survival compared with sunitinib in treatment-naïve patients with advanced RCC regardless of PD-L1 expression.
SELECTED
LANGUAGE


Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses approved and investigational therapies in renal cell carcinoma (RCC).

To date, physicians have access to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with poor- and intermediate-risk RCC. In the CheckMate-214 trial, the combination outperformed single-agent sunitinib (Sutent) in patients with metastatic RCC.

There are a number of other combinations that are being examined, adds Stadler, including PD-1 inhibitors combined with various VEGFR inhibitors. Most of the data with combinations are still pending, but in September, positive results were reported with the combination of avelumab (Bavencio) and axitinib (Inlyta). The combination was reported to show a significant improvement in progression-free survival compared with sunitinib in treatment-naïve patients with advanced RCC regardless of PD-L1 expression.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x